IRIS
BUTTITTA, Fiamma
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.031
AS - Asia 3.632
EU - Europa 3.582
SA - Sud America 455
AF - Africa 52
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 7
Totale 12.769
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.919
SG - Singapore 1.534
CN - Cina 1.007
UA - Ucraina 540
IT - Italia 490
IE - Irlanda 481
GB - Regno Unito 445
SE - Svezia 401
RU - Federazione Russa 381
BR - Brasile 371
TR - Turchia 324
VN - Vietnam 316
FR - Francia 302
DE - Germania 251
IN - India 161
FI - Finlandia 117
CA - Canada 61
HK - Hong Kong 54
PL - Polonia 39
AR - Argentina 37
MX - Messico 37
IQ - Iraq 32
JP - Giappone 27
KR - Corea 27
BD - Bangladesh 25
CZ - Repubblica Ceca 25
NL - Olanda 21
BE - Belgio 20
ES - Italia 19
TW - Taiwan 19
ID - Indonesia 16
PK - Pakistan 16
ZA - Sudafrica 14
AT - Austria 13
EC - Ecuador 12
SA - Arabia Saudita 11
IL - Israele 10
LT - Lituania 10
MA - Marocco 9
CO - Colombia 8
IR - Iran 8
MY - Malesia 8
PY - Paraguay 8
VE - Venezuela 8
AU - Australia 7
CL - Cile 7
EU - Europa 7
AE - Emirati Arabi Uniti 6
LB - Libano 6
BA - Bosnia-Erzegovina 5
ET - Etiopia 5
JO - Giordania 5
KE - Kenya 5
TN - Tunisia 4
AZ - Azerbaigian 3
CH - Svizzera 3
DZ - Algeria 3
EG - Egitto 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PH - Filippine 3
SN - Senegal 3
TT - Trinidad e Tobago 3
UG - Uganda 3
CR - Costa Rica 2
DK - Danimarca 2
EE - Estonia 2
JM - Giamaica 2
MK - Macedonia 2
NI - Nicaragua 2
NP - Nepal 2
RO - Romania 2
RS - Serbia 2
UY - Uruguay 2
UZ - Uzbekistan 2
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
GA - Gabon 1
GD - Grenada 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LU - Lussemburgo 1
MM - Myanmar 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
SC - Seychelles 1
SV - El Salvador 1
Totale 12.768
Salva come PNG Salva come JPEG
Città #
Singapore 1.154
Chandler 653
Jacksonville 610
San Jose 520
Dublin 471
Ashburn 349
Southend 264
Beijing 262
Princeton 231
Dallas 197
Izmir 188
Nanjing 186
Los Angeles 141
Santa Clara 129
Cambridge 101
Dearborn 101
Ho Chi Minh City 93
The Dalles 90
Wilmington 90
New York 87
Tongling 82
Altamura 71
Boardman 70
Ann Arbor 67
Chieti 63
Munich 63
Hanoi 62
Nanchang 57
Pescara 49
Shenyang 49
Buffalo 47
Hong Kong 46
Moscow 38
São Paulo 35
Warsaw 32
Council Bluffs 29
Tianjin 29
Hangzhou 27
Hebei 26
Milan 26
Rome 26
Seoul 26
Woodbridge 26
Chennai 25
Redondo Beach 24
Kunming 23
Stockholm 22
Atlanta 21
Grevenbroich 21
Tokyo 21
Washington 21
Orem 20
Boston 19
Brooklyn 19
Augusta 18
Denver 18
Montreal 18
Toronto 17
Brussels 16
London 16
Poplar 16
Baghdad 15
Da Nang 15
Houston 15
Jiaxing 15
Mexico City 15
Chicago 14
Helsinki 14
Jinan 14
Norwalk 14
Phoenix 14
San Mateo 14
Taichung 14
Biên Hòa 13
Brno 13
Ningbo 13
Belo Horizonte 12
Collecorvino 12
Rio de Janeiro 12
Frankfurt am Main 11
New Delhi 11
Orange 11
Turku 11
Changsha 10
Nuremberg 10
Haiphong 9
Hefei 9
Dong Ket 8
Johannesburg 8
Latina 8
Montesilvano 8
Ninh Bình 8
San Francisco 8
Vienna 8
Amsterdam 7
Auburn Hills 7
Guangzhou 7
Hyderabad 7
Hải Dương 7
Manchester 7
Totale 7.746
Salva come PNG Salva come JPEG
Nome #
Assessing EGFR mutations. 242
ALK protein analysis by IHC staining after recent regulatory changes: A comparison of two widely used approaches, revision of the literature, and a new testing algorithm 212
A unique microRNA signature associated with plaque instability in humans. 200
Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays 182
ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: Results of the first italian external quality assurance scheme 179
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: Toward a real-time liquid biopsy for treatment 177
Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. 172
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors 160
Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control 154
A unique microRNA signature associated with ischemic stroke in humans 152
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. 151
ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm 148
AKT1(E17K) in human solid tumours 144
Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. 143
Down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome. 141
Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle 140
ABCA-1 expression is reduced in atherosclerotic plaques from hypertensive patients: a new potential link between hypertension and atherosclerosis 138
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 137
Reduction of atherothrombotic burden before stent deployment in non-ST elevation acute coronary syndromes: Reduction of myocardial necrosis achieved with nose-dive manual thrombus aspiration (REMNANT) trial. A volumetric intravascular ultrasound study 137
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. 136
Int6 expression can predict survival in early-stage non-small cell lung cancer patients. 136
ATP-binding cassette transporter A1 (ABCA1) overexpression in hypercholesterolemic plaques: a potential molecular explanation 135
Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. 134
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. 133
Overexpression of ABCA1 in human plaques exposed to hypercholesterolemia: the role of microRNA modulation 132
POLE exonuclease domain mutations in endometrial carcinoma: a case report 131
Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. 130
Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. 129
Mutational profile of GNAQQ209 in human tumors. 129
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 129
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. 128
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. 127
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 125
Absence of somatic mutations in the coding region of the waf1/cip1 gene in human breast, lung and ovarian carcinomas - a polymorphism at codon-31. 124
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 124
Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation 123
Survivin gene expression in early-stage non-small cell lung cancer. 122
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. 121
Association between cigarette smoking and FHIT gene alterations in lung cancer. 121
Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications. 121
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 119
Correspondence - In Reply - Limitations of Single-Strand Conformation Polymorphism Analysis As a High-Throughput Method for the Detection of EGFR Mutations in the Clinical Setting 118
Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. 118
Hypertension is a determinant of ABCA1 expression in atherosclerotic plaques from hypercholesterolemic patients 118
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. 118
An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments 118
microRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer. 116
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. 115
Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients 115
mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients. 114
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. 114
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 114
Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up 113
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. 113
Lung tumours from non-smoking subjects: A p53-related genetic instability in a subset of cases. 112
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 112
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. 112
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 112
Telomerase activity as a prognostic indicator in Stage I Non- Small Cell Lung Cancer -Gruppo Italiano di Patologia Molecolare II Riunione Scientifica. Pisa 20-22 Giugno99 111
p53 alterations in non-small cell lung cancer correlate with metastatic involvement of hilar and mediastinal lymph nodes 111
The chromosomal location of the mouse mammary tumor gene Int6 and related pseudogenes in the mouse genome. 111
mdm2 gene alterations and mdm2 protein expression in breast carcinomas 110
Enriched SSCP: a highly sensitive method for the detection of unknown mutations. Application to the molecular diagnosis of lung cancer in sputum samples. 109
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies 108
Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations 108
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 107
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. 106
Host genetic background effect on the frequency of mouse mammary tumor virus-induced rearrangements of the int-1 and int-2 loci in mouse mammary tumors. 105
Hypertension modulates miR-145 expression in human atherosclerotic plaques 105
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. 103
Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia. 102
The chromosome location of the human homolog of the mouse mammary tumor-associated gene INT6 and its status in human breast carcinomas. 102
Detection of gene mutations on cytological specimens: clinical implications 100
Nucleotide and deduced amino acid sequences of tumor gene INT6. 100
Bronchioloalveolar carcinoma: K-ras mutations are constant events in the mucinous subtype 98
PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy 97
BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients 97
Prostatic cancer: molecular bases. 96
Genetic analysis of lung tumors of non-smoking subject: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus 94
Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. 94
Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. 94
Real-world data on NGS diagnostics: A survey from the Italian Society of Pathology (SIAPeC) NGS Network 93
p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. 90
Predictive markers in lung cancer: A few hints for the practicing pathologist 90
Identification of microRNAs 758 and 33b as potential modulators ofABCA1 expression in human atherosclerotic plaques 90
Telomerase Activity as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer 89
Evaluation of FHIT gene alterations in ovarian cancer 89
p53 mutations and histologic type of invasive breast carcinoma. A polymerase chain reaction-single-strand conformation polymorphism and immunohistochemical analysis. 88
Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma. 87
Stabilita’ del dna in campioni citologici conservati in fase liquida 86
p53 mutations and histological type of invasive breast carcinoma. 85
Reduced expression of INT-6/eIF3-p48 in human tumors. 82
BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report 81
Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. 81
Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients 81
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. 81
P53 and C-erbb-2 alterations in in-situ and invasive ductal breast carcinomas - a genetic and immunohistochemical analysis. 80
Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. 79
p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. 79
Cell cycle-related gene abnormalities and product expression in esophageal carcinoma. 76
Totale 11.845
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.882
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.882
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021135 0 0 0 0 0 0 0 0 0 93 6 36
2021/2022603 18 7 8 131 31 23 13 38 50 33 84 167
2022/20231.709 144 216 70 212 193 345 96 105 233 12 46 37
2023/2024762 68 24 44 23 50 229 153 33 4 27 2 105
2024/20252.249 114 451 376 49 56 74 81 88 235 103 246 376
2025/20263.886 351 245 376 563 478 283 626 280 424 260 0 0
Totale 13.013